Tempus AI, Inc. - SIC # 8071 - MEDICAL LABORATORIES

Ticker Exchange SIC # Website Latest Ticker
TEM Nasdaq 8071 www.tempus.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tempus AI, Inc.

Tempus AI (TEM) On Its Personalis Deal And Whether The Bull Case Is Priced In - Jul 21st, 2026 6:19 pm
Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion - Jul 21st, 2026 6:30 am
Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal - Jul 21st, 2026 5:43 am
Tempus AI (TEM) Is Buying Personalis For $1.5 Billion To Deepen Cancer Monitoring - Jul 21st, 2026 3:10 am
Tempus AI (TEM) Stock May Be A Bargain Despite Its 22% Slump - Jul 21st, 2026 2:09 am
Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal - Jul 20th, 2026 2:56 pm
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive - Jul 20th, 2026 2:27 pm
TEM, PSNL Stocks Are Falling — Why Morgan Stanley Still Likes Tempus AI’s Personalis Deal - Jul 20th, 2026 1:38 pm
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink - Jul 20th, 2026 1:31 pm
Sector Update: Healthcare Stocks Fall Late Afternoon - Jul 20th, 2026 1:27 pm
Tempus AI to Buy Cancer Test Maker Personalis; Needham Says Deal Premium Well Above Peers - Jul 20th, 2026 1:19 pm
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition - Jul 20th, 2026 10:02 am
Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B - Jul 20th, 2026 9:23 am
TEM’s Deal To Acquire PSNL Opens Door For $20B Cancer Market Opportunity – Retail Awaits To See Execution - Jul 20th, 2026 9:11 am
Tempus to buy cancer test maker Personalis for $1.5B - Jul 20th, 2026 8:38 am
Tempus AI to Acquire Personalis in $1.5 Billion Deal - Jul 20th, 2026 6:56 am
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform - Jul 20th, 2026 6:35 am
Dow drops 300 points as chip rally fades ahead of Big Tech earnings - Jul 20th, 2026 5:48 am
Merck Reportedly Goes To Bat In Takeover Battle. But Genomics Stock Reverses. - Jul 17th, 2026 2:12 pm
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service - Jul 16th, 2026 6:30 am